Global Biologic Drugs Market to Jump to Over $220 Billion by 2019
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 08/14/13 -- TriMarkPublications.com cites in its newly published " and Biosimilars World Markets" report that the global drugs market will jump to over $220 billion by 2019. For more information, visit: .
, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of sales, followed by the E.U. (21%) and Japan (9%).
The " and Biosimilars World Markets" report covers key and biosimilar drugs, including:
Humira (Adalimumab)
Remicade (Infliximab)
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Privigen (Immune Globulin Intravenous)
Perjeta (Pertuzumab)
Soliris (Eculizumab)
Eylea (Aflibercept)
Revlimid (Lenalidomide)
Herceptin (Trastuzumab)
Gardasil
Varivax (Varicella Virus Vaccine Live)
Gammagard Liquid (Immune Globulin Infusion (Human))
Aranesp (Darbepoetin Alfa)
Enbrel (Etanercept)
Epogen/Procrit/Eprex/Erypo (Epoetin Alfa)
Genotropin (Somatropin)
Herceptin (Trastuzumab)
Humira (Adalimumab)
Neulasta (Pegfilgrastim)
Neupogen (Filgrastim)
Remicade (Infliximab)
Rituxan/MabThera (Rituximab)
The " and Biosimilars World Markets" report examines companies manufacturing and biosimilar equipment and supplies in the world. Companies covered include: 3Bio, Abbott, AbbVie, Actelion, Amgen, Amoytop, Anhui Anke, Apotex, Astellas, AstraZeneca, Bayer, Beijing Four Rings, Bharat Serums and Vaccines, Biocon, Biogen Idec, Bioton, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cipla, Dr. Reddy's, Elan, Eli Lilly, Gideon Richter, Gilead Sciences, GlaxoSmithKline, Hospira, Intas, Johnson & Johnson, Merck, Mylan, Novartis, Pfizer, Roche, Sandoz, Sanofi, Stada Arzneimittel Aktiengesellschaft, Teva and Watson.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2013 - 17:45 Uhr
Sprache: Deutsch
News-ID 287830
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Global Biologic Drugs Market to Jump to Over $220 Billion by 2019"
steht unter der journalistisch-redaktionellen Verantwortung von
TriMarkPublications.com (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
